Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Neurodegenerative Disease Market Valued at Present and by 2029?

In recent times, there has been a robust increase in the market size of neurodegenerative diseases. It’s forecasted to rise from $52.3 billion in 2024 to $57.23 billion in 2025, growing at a Compound Annual Growth Rate (CAGR) of 9.4%. This surge over the historical period can be credited to an improvement in diagnostic abilities, growing demand for treatments addressing symptoms, an expansion in clinical research, an increase in collaborations between public and private entities, and a rising pressure due to unfulfilled medical needs.

Anticipations of substantial expansion are predicted for the neurodegenerative disease market size in the subsequent years. By 2029, it is projected to escalate to $81.23 billion, signifying a compound annual growth rate (CAGR) of 9.2%. This prospective augmentation during the predictive stretch can be credited to factors such as advancements in gene and cell therapy, the growing uptake of digital biomarkers, an increasing inclination towards precision medicine methodologies, an expanding roster of disease-altering drugs, and the rising application of artificial intelligence into the field of neurology. Key trends expected during the forecast period encompass progression in neuroimaging techniques, refined drug delivery systems intended for brain targeting, the formulation of individualized treatment approaches, breakthroughs in biomarker discovery, and advancements in gene editing technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp

#What Drivers Are Influencing Growth In The Neurodegenerative Disease Market?

The neurodegenerative disease market is expected to be propelled by an upsurge in research and clinical trials. Clinical trials involve human subjects in research studies to evaluate the efficacy, safety and potential side effects of new medical devices, drugs or treatments. The amplification in research and clinical trials is largely fueled by the increasing demand for novel treatments to meet growing healthcare demands and optimize patient results. Clinical trials back up neurodegenerative disease research by providing indispensably crucial data on the safety and effectiveness of new treatments, thereby fostering therapeutic development and improving patient results. For example, a report released by the UK-based Association of the British Pharmaceutical Industry (ABPI) in November 2023 stated that the total number of industry clinical trials initiated each year in the UK rose slightly by 4.3%, increasing from 394 trials in 2021 to 411 in 2022. Hence, the upward trend in research and clinical trials is anticipated to propel the expansion of the neurodegenerative disease market.

What Are The Main Segments Identified In The Neurodegenerative Disease Market Research?

The neurodegenerative disease market covered in this report is segmented –

1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospital, Retail, Online

Subsegment:

1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism

2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)

4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Are The Leading Trends And Opportunities In The Neurodegenerative Disease Sector?

Key players in the neurodegenerative disease market are channeling their efforts into creating novel products such as next-generation adaptive Deep Brain Stimulation (aDBS) systems. These endeavours are driven by the intention to enhance treatment accuracy, augment disease-altering impacts, and uplift the patient’s quality of life. The next-generation adaptive deep brain stimulation (aDBS) systems, being advanced neurostimulation tools, are geared towards offering real-time, tailor-made treatment for Parkinson’s disease. These systems achieve this by dynamically tweaking stimulation parameters depending on neural feedback to maximize therapeutic benefits and mitigate side effects, thereby ensuring improved patient outcomes. For example, in February 2025, Medtronic, a medical technology firm based in the US, obtained approval from the U.S. Food and Drug Administration (USFDA) for the first-ever adaptive deep brain stimulation (aDBS) system for Parkinson’s disease. This approval corresponds to the premarket approval (PMA) application for the Percept RC neurostimulator integrated with BrainSense technology, which auto-adjusts therapy according to a patient’s brain signals. This system is clinically proven to alleviate symptoms for advanced Parkinson’s disease patients, marking a considerable progress in personalized neuromodulation treatments.

Which Companies Play A Key Role In The Development Of The Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report

What Are The Key Regional Developments Shaping The Neurodegenerative Disease Market?

North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24618&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model